Abbott Laboratories (NYSE:ABT) has a beta value of 0.71 and has seen 1.05 million shares traded in the recent trading session. The company, currently valued at $227.42B, closed the recent trade at $130.71 per share which meant it lost -$1.32 on the day or -1.00% during that session. The ABT stock price is -8.05% off its 52-week high price of $141.23 and 23.72% above the 52-week low of $99.71. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.12 million shares traded. The 3-month trading volume is 6.29 million shares.
The consensus among analysts is that Abbott Laboratories (ABT) is Buy stock at the moment, with a recommendation rating of 1.90. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 13 have rated it as a Hold, with 12 advising it as a Buy. 0 have rated the stock as Underweight.
Abbott Laboratories (NYSE:ABT) trade information
Sporting -1.00% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ABT stock price touched $130.71 or saw a rise of 3.21%. Year-to-date, Abbott Laboratories shares have moved 25.47%, while the 5-day performance has seen it change -1.99%. Over the past 30 days, the shares of Abbott Laboratories (NYSE:ABT) have changed -4.21%. Short interest in the company has seen 20.8 million shares shorted with days to cover at 3.54.
Wall Street analysts have a consensus price target for the stock at $140, which means that the shares’ value could jump 6.64% from the levels at last check today.. The projected low price target is $140.0 while the price target rests at a high of $140.0. In that case, then, we find that the latest price level in today’s session is -7.11% off the targeted high while a plunge would see the stock gain -7.11% from the levels at last check today..
Abbott Laboratories (ABT) estimates and forecasts
The company’s shares have gained 16.38% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 29.98% over the past 5 years. Earnings growth for 2025 is a modest 10.47% while over the next 5 years, the company’s earnings are expected to increase by 10.38%.
ABT Dividends
Abbott Laboratories is expected to release its next earnings report on 2025-Apr-16 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 2.32 at a share yield of 1.77%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 1.67%.
Abbott Laboratories (NYSE:ABT)’s Major holders
Insiders own 0.54% of the company shares, while shares held by institutions stand at 80.49% with a share float percentage of 80.93%. Investors are also buoyed by the number of investors in a company, with Abbott Laboratories having a total of 3883.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 166.35 million shares worth more than $17.29 billion. As of 2024-06-30, VANGUARD GROUP INC held 9.5932% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 131.13 million shares as of 2024-06-30. The firm’s total holdings are worth over $13.63 billion and represent 7.5619% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund . As of Mar 31, 2025 , the former fund manager holds about 3.15% shares in the company for having 54.8 shares of worth $7.18 billion while later fund manager owns 48.19 shares of worth $6.31 billion as of Mar 31, 2025 , which makes it owner of about 2.77% of company’s outstanding stock.
